Targeting Nanocarriers with Anisamide: Fact or Artifact?

Area of Science:

• Nanomedicine
• Cancer Therapeutics
• Drug Delivery Systems

Background:

• Nanoparticle encapsulation of chemotherapeutics can minimize side effects and enhance antitumor activity.
• Surface modification of nanocarriers with tumor-targeting ligands aims to improve specificity for cancer cells.
• Anisamide, a benzamide derivative, has been explored as a tumor-directing moiety in functionalized nanosystems, purportedly interacting with Sigma receptors.

Purpose of the Study:

• To critically review anisamide-tethered nanocarrier formulations for tumor targeting.
• To evaluate the evidence for anisamide's interaction with Sigma receptors and its role in cancer.
• To assess the variability in antitumor efficacy and tumor deposition of anisamide-decorated nanosystems.

Main Methods:

• Review of published literature on anisamide-tethered nanocarrier formulations.
• Analysis of in vivo studies investigating the antitumor efficacy of these nanosystems.
• Discussion of anisamide's putative cellular target, the Sigma-1 receptor, its localization, and cancer implications.

Main Results:

• Data on the antitumor efficacy of anisamide-decorated nanosystems show considerable variability across studies.
• Evidence questioning the interaction between anisamide and Sigma receptors was identified.
• The tumor deposition and antitumor efficacy of anisamide-modified drug carriers are inconsistent.

Conclusions:

• The tumor-targeting effect of anisamide in nanocarrier systems is questionable due to inconsistent findings.
• The interaction of anisamide with Sigma receptors requires further investigation.
• More research is necessary to determine the actual utility of anisamide for tumor targeting in nanomedicine.